PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34867458-15 2021 Conclusion: Our findings showed that combination EX + CR intervention effectively decreased CRP, IL-6, and TNF-alpha in overweight and obese adults with active lifestyles, but not with sedentary lifestyle behavior. Chromium 54-56 C-reactive protein Homo sapiens 92-95 34799157-7 2022 It was found that blood Cr level showed significant dose-dependent relationships with increasing of MNF and urinary 8-OHdG, while negative association with CRP and C1q. Chromium 24-26 C-reactive protein Homo sapiens 156-159 34799157-9 2022 4.97% of the association between blood Cr level and the increased MNF was mediated by CRP. Chromium 39-41 C-reactive protein Homo sapiens 86-89 33321447-0 2021 Effect of chromium supplementation on hs-CRP, TNF-alpha and IL-6 as risk factor for cardiovascular diseases: A meta-analysis of randomized-controlled trials. Chromium 10-18 C-reactive protein Homo sapiens 41-44 33321447-1 2021 BACKGROUND: The objective of this systematic review is to assess the relationship between chromium supplementation and inflammatory biomarkers levels (hs-CRP, TNF-alpha, IL-6) as risk factor for cardiovascular diseases. Chromium 90-98 C-reactive protein Homo sapiens 154-157 29096935-16 2018 At 1st follow-up, CR (ITAS2010 = 0, CRP < 6mg/L and non-progressive disease on angiography) was observed in 173 (68.9%), partial response (PR) in 42 (16.7%) and no response was seen in only 36 (14%) patients. Chromium 18-20 C-reactive protein Homo sapiens 36-39 30546347-6 2018 Results: Chromium supplementation led to a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (-1.4 +- 1.5 vs. + 0.2 +- 2.2 mg/L, p = 0.01) compared with the placebo. Chromium 9-17 C-reactive protein Homo sapiens 91-109 32291175-9 2020 CONCLUSION: These results confirm that CR-POAP, defined as POD1 serum AMS >100 U/l and POD2 CRP >= 180 mg/l, is associated with an increased risk of CR-POPF. Chromium 39-41 C-reactive protein Homo sapiens 92-95 21224533-10 2010 Serum CRP levels at the time of 2W after CRT initiation (CRT2W) in CR group were low compared to those in non-CR group (p=0.071). Chromium 41-43 C-reactive protein Homo sapiens 6-9 29301121-5 2018 The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0.024) and C-reactive protein (CRP; p = 0.004). Chromium 4-6 C-reactive protein Homo sapiens 120-138 29301121-5 2018 The CR rate was significantly low in patients who had elevated levels of soluble interleukin-2 receptor (p = 0.024) and C-reactive protein (CRP; p = 0.004). Chromium 4-6 C-reactive protein Homo sapiens 140-143 24924751-7 2014 The uNGAL/Cr level was correlated with serum levels of white blood cells, C-reactive protein, CysC and with uKIM-1/Cr (P < 0.05). Chromium 10-12 C-reactive protein Homo sapiens 74-92 22583484-8 2012 Systolic and diastolic blood pressure, serum albumin, LDL-C, HDL-C, Hb, Cr, and Ca were inversely associated with CRP. Chromium 72-74 C-reactive protein Homo sapiens 114-117 21224533-12 2010 The prediction accuracies to discriminate CR from non-CR by CRP<=0.1 were 50%, 82%, and 75% in sensitivity, specificity and accuracy, respectively. Chromium 42-44 C-reactive protein Homo sapiens 60-63 21224533-12 2010 The prediction accuracies to discriminate CR from non-CR by CRP<=0.1 were 50%, 82%, and 75% in sensitivity, specificity and accuracy, respectively. Chromium 54-56 C-reactive protein Homo sapiens 60-63 17389710-8 2007 These CR- and EX-induced energy deficits were accompanied by reductions in most of the major CHD risk factors, including plasma LDL-cholesterol, total cholesterol/HDL ratio, HOMA-IR index, and CRP concentrations that were similar in the two intervention groups. Chromium 6-8 C-reactive protein Homo sapiens 193-196 15163463-12 2004 There was significant positive correlation between CRP and DIVCi (r=0.43, p <0.05) and IVCe (r=0.45, p <0.05) and between serum albumin and creatinine dialysate-to-plasma ratio (D/P Cr, r=0.57, p <0.01). Chromium 188-190 C-reactive protein Homo sapiens 51-54 15340176-8 2004 Patients with dominant ER had higher levels of serum C-reactive protein (CRP) compared with levels in patients with dominant CR and patients with mixed remodeling (1.62 mg/dL +/- 2.05 [standard deviation] vs 0.19 mg/dL +/- 0.33 and 0.21 mg/dL +/- 0.39, respectively, P < .005). Chromium 73-75 C-reactive protein Homo sapiens 53-71 16983929-16 2006 We conclude that elevated CRP is associated with lower RRF As a predictor of mortality, CRP may be better than RRF and D/P Cr. Chromium 123-125 C-reactive protein Homo sapiens 26-29 11499569-10 2001 When patients were divided in two groups according to renal function, CRP resulted 7.4+/-6.3 mg/L in the group of patients with a C(Cr) lower than 20 mL/min (n=32) and 2.76+/-4.35 in the group of patients with a C(Cr) higher than 20 mL/min (n = 70) (p <0.0001). Chromium 132-134 C-reactive protein Homo sapiens 70-73 11274243-4 2001 Patients with an elevated CRP (>6 mg/L; n = 29) had significantly reduced plasma prealbumin (0.36 +/- 0.02 versus 0.44 +/- 0.03 g/L; P: < 0.05), decreased total weekly creatinine clearance (C(Cr); 52.5 +/- 2.3 versus 63.1 +/- 3.2 L/1.73 m(2); P: < 0.01), and increased left ventricular thickness (1.24 +/- 0.05 versus 1.08 +/- 0.06 cm; P: < 0.05) at baseline compared with those who had a normal CRP (< or =6 mg/L; n = 21). Chromium 198-200 C-reactive protein Homo sapiens 26-29 10886221-3 2000 A strong inhibition of IL-6 activity evaluated by quantification of C-reactive protein was observed in all patients and was correlated with the high CR rate achieved with this combination therapy. Chromium 149-151 C-reactive protein Homo sapiens 68-86